More precisely, persistent STAT3 activation mediates SHH pathway activation in stromal cells, which subsequently leads to an enhanced desmoplastic stromal response through paracrine stimulation of CAFs/PSCs, increased tumor growth, and resistance to gemcitabine, the chemotherapeutic standard of care for PDAC [35] (Figure 2B). This evidence concerns the gene STAT3 and neoplasm.